Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465430 | 0.80 | MEN1 (0.34) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL3464165 | 0.79 | HSP90B1 (0.44) | MEN1KMT2AHSP90B1TRAP1HSP90AA1 | |
| SCHEMBL3465442 | 0.76 | RAB9A (0.46) | ALDH1A1MEN1KMT2AHSP90B1TRAP1 | |
| SCHEMBL3465264 | 0.76 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL13971466 | 0.72 | MEN1 (0.35) | ALDH1A1MEN1KMT2AHSP90B1TRAP1 | |
| SCHEMBL3465261 | 0.72 | HSP90AA1 (0.36) | MEN1KMT2AHSP90B1TRAP1HSP90AA1 | |
| SCHEMBL3465260 | 0.70 | HSP90AA1 (0.64) | HSP90B1TRAP1HSP90AA1HSP90AB1 | |
| SCHEMBL3464752 | 0.69 | CYP1A2 (0.53) | ALDH1A1MEN1KMT2AHSP90B1TRAP1 | |
| SCHEMBL3464597 | 0.65 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1 | |
| SCHEMBL7721154 | 0.63 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | claimed |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 1875/4885MEN1 4594/4885KMT2A 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.